Published online Aug 24, 2019. doi: 10.5306/wjco.v10.i8.283
Peer-review started: February 27, 2019
First decision: April 11, 2019
Revised: May 5, 2019
Accepted: July 30, 2019
Article in press: July 30, 2019
Published online: August 24, 2019
Core tip: Castrate testosterone level of less than 20 ng/dL achieved after primary radiotherapy plus androgen deprivation treatment for non-metastatic prostate cancer is associated with better biochemical relapse free survival. Testosterone level of < 50 ng/dL has been used to define castrate level after surgery or after androgen deprivation treatment in metastatic prostate cancer (PC). In this study, we evaluated the effect of two different castrate testosterone levels, < 50 and < 20 ng/dL, on biochemical relapse free survival in patients with non-metastatic intermediate and high risk PC receiving definitive modern radiotherapy and androgen deprivation treatment. With a median follow up of 125 mo we found that castrate testosterone level of less than 20 ng/dL achieved after primary radiotherapy plus androgen deprivation treatment was found to be associated with better biochemical relapse free survival.